

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Lupin Ltd
Deal Size : $75.0 million
Deal Type : Acquisition
Lupin Signs Agreement to Acquire Two Inhalation Brands from Sunovion
Details : The acquisition of Brovana® (arformoterol tartrate) Inhalation Solution and Xopenex HFA® (levalbuterol tartrate) Inhalation Aerosol brands expands Lupin’s portfolio of inhalation products in the U.S. and strengthens the company’s presence in the re...
Product Name : Brovana
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 20, 2022
Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Lupin Ltd
Deal Size : $75.0 million
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Arformoterol Tartrate inhalation solution, EQ 0.015 mg Base/2 ml is indicated for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with COPD, including chronic bronchitis and emphysema.
Product Name : Arformoterol Tartrate-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 24, 2022
Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cipla Receives Final Approval for Generic Version Of Sunovion Pharmaceuticals, Inc.'s Brovana®
Details : Cipla’s Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana®.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 23, 2021
Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Launches Authorized Generic Version of Brovana® in the United States
Details : Arformoterol Tartrate Inhalation Solution 15mcg/2mL, is indicated for the long-term, twice daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. It is for us...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 03, 2021
Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Arformoterol Tartrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 27, 2014
Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Sumitomo Pharma America
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease
Details : Arformoterol is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 12, 2011
Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Sumitomo Pharma America
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Sumitomo Pharma America
Deal Size : Inapplicable
Deal Type : Inapplicable
Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography
Details : Arformoterol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 27, 2011
Lead Product(s) : Arformoterol Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Sumitomo Pharma America
Deal Size : Inapplicable
Deal Type : Inapplicable
